Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + irinotecan followed by panitumumab + AMG 479 in metastatic colorectal cancer (WT KRAS)
2008-004752-77Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab, irinotecan and ganitumab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Amgen. Primary endpoint: Emergence of mutant KRAS. Started Nov 2008; status: completed.
02
Drugs
panitumumabirinotecanganitumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-004752-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004752-77.